Photo from wikipedia
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRASG12C. It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the… Click to show full abstract
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRASG12C. It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRASG12C mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
Keywords:
krasg12c mutation;
lung cancer;
non small;
small cell;
harboring krasg12c;
cell lung
Journal Title: Current medicinal chemistry
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Current medicinal chemistry
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!